SEARCH:   Advanced

Blood, 15 March 2005, Vol. 105, No. 6, pp. 2300-2306. Prepublished online as a Blood First Edition Paper on November 30, 2004; DOI 10.1182/blood-2004-04-1473. This Article Full Text (PDF) Supplemental Tables All Versions of this Article: 2004-04-1473v1 105/6/2300    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cao, T. M Articles by Lowsky, R. Search for Related Content PubMed PubMed Citation Articles by Cao, T. M Articles by Lowsky, R. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 16, 2004 Accepted November 15, 2004 Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose Thai M Cao*, Judith A Shizuru, Ruby M Wong, Kevin Sheehan, Ginna G Laport, Keith E Stockerl-Goldstein, Laura J Johnston, Monic J Stuart, Janice M Brown, F C Grumet, Robert S Negrin, and Robert Lowsky Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Division of Hematology, Department of Medicine, Current Address: University of Utah School of Medicine, Salt Lake City, UT, USA Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA Department of Health Research and Policy, Stanford University, Stanford, CA, USA Stanford Cellular Therapeutics and Transplantation Laboratory, Stanford Hospital and Clinics, Stanford, CA, USA Histocompatibility Laboratory, Stanford Medical School Blood Center, Palo Alto, CA, USA; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA * Corresponding author; email: thai.cao{at}hsc.utah.edu. The influence of graft composition on clinical outcomes after reduced-intensity conditioning is not well characterized. In this report we prospectively enumerated CD34+, CD3+, CD4+, and CD8+ cell doses in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) allografts in 63 patients transplanted following non-myeloablative conditioning with total body irradiation 200 cGy plus fludarabine as treatment for malignant diseases. Donors were HLA-identical siblings (n = 38) or HLA-matched unrelated individuals (n = 25). By univariate analyses G-PBMC CD8+ T-cell dose the 50th percentile favorably correlated with full donor blood T-cell chimerism (P = .03), freedom from progression (P = .001) and overall survival (P = .03). No G-PBMC cell dose influenced grade II - IV acute or extensive chronic graft-versus-host disease. In multivariate analysis only G-PBMC CD8+ T-cell dose (P = .003; RR = 0.2, 95% CI = 0.1-0.6) was associated with improved freedom from progression. Infusion of low G-PBMC CD8+ T-cell dose for non-myeloablative allografting may adversely affect T-cell engraftment and survival outcome. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. A. Pulsipher, P. Chitphakdithai, B. R. Logan, S. F. Leitman, P. Anderlini, J. P. Klein, M. M. Horowitz, J. P. Miller, R. J. King, and D. L. Confer Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose Blood, September 24, 2009; 114(13): 2606 - 2616. [Abstract] [Full Text] [PDF] F. Baron, R. Storb, B. E. Storer, M. B. Maris, D. Niederwieser, J. A. Shizuru, T. R. Chauncey, B. Bruno, S. J. Forman, P. A. McSweeney, et al. Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation J. Clin. Oncol., September 1, 2006; 24(25): 4150 - 4157. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020